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Abstract 
Initially developed in 1992 as an MR imaging agent, the family of protected graft copolymers 
(PGC) is based on a conjugate of polylysine backbone to which methoxypoly(ethylene glycol) 
(MPEG) chains are covalently linked in a random fasion via N--amino groups. While PGC is 
relatively simple in terms of its chemcial composition and structure, it has proved to be a 
versatile platform for in vivo drug delivery. The advantages of poly amino acid backbone 
grafting include multiple available linking sites for drug and adaptor molecules. The grafting of 
PEG chains to PGC does not compromise biodegradability and does not result in measurable 
toxicity or immunogenicity. In fact, the biocompatablility of PGC has resulted in its being one 
of the few 100% synthetic non-proteinaceous macromolecules that has suceeded in passing 
the initial safety phase of clinical trials. PGC is capable of long circulation times after injection 
into the blood stream and as such found use early on as a carrier system for delivery of 
paramagnetic imaging compounds for angiography. Other PGC types were later developed 
for use in nuclear medicine and optical imaging applications in vivo. Recent developments in 
PGC-based drug carrier formulations include the use of zinc as a bridge between the PGC 
carrier  and  zinc-binding  proteins  and  re-engineering  of  the  PGC  carrier  as  a  covalent 
amphiphile that is capabe of binding to hydrophobic residues of small proteins and peptides. 
At present, PGC-based formulations have been developed and tested in various disease 
models for: 1) MR imaging local blood circulation in stroke, cancer and diabetes; 2) MR and 
nuclear imaging of blood volume and vascular permeability in inflammation; 3) optical imaging 
of proteolytic activity in cancer and inflammation; 4) delivery of platinum(II) compounds for 
treating cancer; 5) delivery of small proteins and peptides for treating diabetes, obesity and 
myocardial  infarction.  This  review  summarizes  the  experience  accumulated  by  various 
research groups that chose to use PGC as a drug delivery platform. 
Key  words:  contrast  agent,  gaft-copolymer,  poly(ethylene  glycol),  chelate,  paramagnetic, 
gadolinium. 
1. Introduction 
PGCs are relatively simple covalent conjugates 
composed of a poly-l-lysine (PLL) backbone which is 
covalently  grafted  with  a  plurality  of  carboxylated 
methoxypoly(ethylene glycol) (MPEG) side chains via 
the N--amino groups of PLL (Fig. 1). The structure of 
graft  copolymers  that  will  be  reviewed  below  is 
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diferent  from  di-  and  multi-  head-to-tail  block 
copolymers  that  were  previously  used  for  drug 
delivery  applications  [1-4].  While  the  latter  usually 
form micelles as a result of interaction between the 
hydrophobic blocks, PGC was specifically designed as 
a  non-aggregating  covalent  macromolecular 
garft-copolymer  conjugate.  As  a  non-modified 
copolymer,  PGC  (also  known  as  PEG-gPLL  or 
MPEGS-PL) carries multiple positive charges and can 
potentially  form  polyionic  complexes  with 
polyanions,  e.g.  plasmid  DNA.  A  host  of  other 
copolymers,  structurally  and  chemcially  similar  to 
PGC, were under consideration as potential non-viral 
gene delivery vehicles in the late 1990s [1-5]. Howev-
er,  despite  the  efficient  formation  of  homogenous 
populations  of  small  (<100  nm)  complexes  with 
plasmid DNA, the in vitro and in vivo efficacy of in-
tracellular  delivery  was  insufficiently  high  to  grant 
further development of protected graft polycations for 
gene delivery [4].  
 
 
Figure  1. PGC  synthesis. Synthesis of a graft copolymer of polylysine and methoxypolyethylene glycol succinate (MPEG)S with 
subsequent modification of free amino groups with diagnostic labels [18] or adaptor molecules for loading of therapeutics (R). The 
synthesis consits of a synthesis of MPEG sulfosuccinimide ester in the presence of water-soluble carbodiimide, acylation of 20-30% of total 
available  amin  groups  of  poly-lysine  followed  by  the  acylation  of  amino  groups  with  an  activated  analog  of  R  (R-x),  usually 
N-hydroxysuccinimide ester. 
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The adaptability of PGCs is in large due to the 
existence of multiple sites on the molecule that can be 
readily  modified  to  carry  theraputic  or  diagnostic 
agents  (Fig  1,  step  2).  A  second  important 
characteristic of PGCs is that they escape the uptake 
during  the  multiple  passes  through  the 
reticuloendothethial system (RES) i.e., they have long 
circulation times and thus can be described as „long 
circulating  agents‟.  This  characteristic  lead  to  their 
initial  use  as  a  carrier  system  for  delivery  of 
paramagnetic  imaging  compounds  for  magentic 
resonance  imaging  (MRI)  [6].  As  such,  the  use  of 
PGCs for in vivo imaging of the blood pool enabled 
visualization of localized morphological and funtional 
abnormalities  in  vascular  permeability  that  allowed 
detection of local inflammation and blood supply of 
tumors. The initial success of PGC as an MR vascular 
imaging agent lead to its further developemnt of the 
PGC  as  a  drug  delivery  platform  as  will  be 
summarized in part two of this review. 
2. PGC: synthesis and structure. 
 In  general,  the  synthesis  of  PGC  involves 
covalent grafting of a polyamino acid with multiple 
MPEG  ester  chains  in  weakly  alkaline  buffered 
aqeous solutions. There are several potential synthetic 
pathways that lead to the desired PGC product, i.e. a 
copolymer of a polyamino acid and covalently grafted 
MPEG chains. They are defined by the reactive side 
chain  groups  of  the  polyamino  acid  and  specific 
reactivity  of  functionalized  MPEG  (Fig.  1).  For 
example,  several  classes  of  biocompatible 
polycarboxylic  acids  can  be  used  as  the  initial 
backbones  for  further  conjugation  with  terminated 
MPEG  chains.  Some  of  these  polycarboxylic 
backbones are biocompatible and biodegradable, such 
as poly-L-glutamic [7] or poly-(α,β)-DL-aspartic acids 
derivatives  [8].  Others,  such  as  uncharged 
N-(2-hydroxypropyl)  methacrylamide  copolymers, 
which are frequently used as backbone polymers, are 
non-biodegradable  but  are  biocompatible  and 
non-immunogenic [9].  
Polylysine  can  be  synthesized  and  purified  to 
yield  homegenous  preparations  with  various 
polydispersity  indeces  (PDI)  and  narrow  mass 
distribution  (i.e.  low  PD=Mw/Mn).  While 
poly-L-lysine (PLL) is readily degradable into smaller 
oligomers  by  many  serine  endopeptidases,  its  poly 
D-enantiomer  is  not,  and  thus  can  be  used  for 
synthesizing  PGCs  with  limited  biodegradability. 
Currently, PLLs with a polydispersity factor of 1.1 are 
commercially available. The synthesis of PLL has been 
perfected through many years of extensive research. 
The  synthesis  includes  a  catalytically  initiated  ionic 
polymerization  process  of  ring  opening  in 
N-carboxy-(N--benzyloxycarbonyl)-L-lysine  anhy-
dride (CBZ-L-lysine NCA) [10]. Most commonly, the 
synthesis is carried out in polar organic solvents in the 
presence  of  diethylamine  as  an  initiator.  Therefore, 
the  synthetic  product  commonly  incorporates  di-
ethylamide bridges and the resultant PLL polymers 
(especially those with low degree of polymerization) 
are  composed  of  two  different  monomers. 
Poly(N--benzyloxycarbonyl) lysines can then be re-
acted with other polymers to yield the formation of 
copolymers  due  to  the  availability  of  free  reactive 
N--amino groups. One of the popular blocks is acti-
vated PEG diester  [11]. A copolymerization of poly 
CBZ-L-lysine results in linear block copolymers that 
are structurally distinct from PGC. These copolymers 
can  then  be  deprotected  and  the  liberated  amino 
groups  used  for  covalent  modification,  if  needed. 
Multiple examples of the use of di- tri- and poly- block 
PLL-PEG copolymers for drug delivery systems exist 
in the literature [12-14].  
Carboxybenzyl  protective  groups  on  poly 
CBZ-L-lysine  can  be  efficiently  removed  using  HBr 
and the resultant purified hydrobromides can be re-
acted with MPEG derivatives in water since PLL has a 
high water solubility at pH<11. At pH 8.5 PLL, exists 
in extended coil conformation with fewer than 10% 
deprotonated  N--amino  groups  [15].  Extended  coil 
conformation of PLL enables efficient access to PLL 
side chain amino groups by hydroxysuccinimide es-
ters  of  MPEG-succinate.  To  prevent  extensive  hy-
drolysis of activated esters of MPEG succinate which 
occur at pH 8.5, we used N-hydroxysulfosuccinimide 
(NHSS)  esters  of  MPEG-succinate  which  were  ob-
tained  in  water  solution  after  modifying 
MPEG-succinate  (MPEGS)  with  water  soluble  car-
bodiimide [16]. The obtained esters are more stable 
than  N-hydroxusuccinimide  esters  at  pH>7.5.  Our 
experience  shows  that  a  25%  modification  of  PLL 
amino groups with MPEGS is sufficient for obtaining 
highly  water  soluble  graft  copolymers  that  can  be 
isolated from the reaction mixture by using ultrafil-
tration [17]. The covalent linking of multiple MPEGS 
chains  to  PLL  results  in  a  large  increase  of  the  hy-
drodynamic diameter. This enables purification based 
on ultrafiltration through hollow fibers with a 100-300 
kD cut-off, depending on the sizes of the initial PLL 
and MPEGS. Such purification results in a complete 
removal of non-reacted hydrolyzed MPEG esters (i.e. 
MPEG succinate and NHSS). However, the purifica-
tion of the obtained graft copolymer (MPEGS-PL) can 
be delayed until all modifications to the amino groups 
of PLL are completed. This is especially convenient if 
the second (or later) component that needs to be co-Theranostics 2012, 2(6) 
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valently linked to MPEGS-PL is soluble in water or 
water-miscible solvent. For example, an excess cyclic 
anhydride  of  diethylenetriaminepentaacetic  acid 
(DTPA) dissolved in DMSO was used in our original 
protocol for obtaining an MPEG-PL-DTPA conjugate 
that can be used for further modification of the re-
maining amino groups of PL as a means of obtaining a 
long-circulating chelating polymer [18]. Notably, on 
the second stage of the synthesis, undesirable cross 
linking of PL with bifunctional DTPA derivatives may 
be greatly reduced or avoided due to the presence of 
grafted MPEGS chains.  
The second and other reactants that are to be at-
tached to the backbone do not have to be soluble in 
water for successful linking to MPEGS-PL. The above 
conjugate forms stable suspensions in chloroform due 
to MPEG solubility in some non-polar solvents, and 
the amino groups remaining on PL after the modifi-
cation with MPEGS esters can be further covalently 
modified in the presence of an organic base (e.g. tri-
ethylamine). The modified product as a rule is more 
soluble in chloroform. For example, for synthesis of 
PGC  carrying  hydrophobic  fatty  acid  chains  or 
cholesteryl hemisuccinate residues, MPEGS-PL can be 
treated  with  chloroform-soluble  activated  esters  of 
fatty acids [19]. Insolubility of MPEGS in diethyl ether 
and ethyl acetate can be further used for precipitating 
the obtained PGC conjugates from choroform which 
greatly simplifies the purification from the excess of 
hydrophobic modifier.  
3. Physico-chemical and biological 
properties of MPEGS-PL-DTPA. 
3.1. Molecular mass and size (hydrodynamic 
radius) 
 Highly-soluble  polycationic  graft  copolymer 
MPEGS-PL was initially used by our group to obtain 
MPEGS-PL-GdDTPA (from here on - abbreviated as 
PGC-DTPAGd)  designed  as  a  biocomaptible 
non-toxic and long-circulating contrast agent (CA) for 
MRI [6]. The molecule consited of MPEG5 succinate (5 
kD)  linked  to  poly-lysine  with  a  degree  of 
polymerization of 250, which was then conjugated to 
DTPA  and  labeled  with  Gd3+  using  transchelation. 
Protective  MPEG  chains  constitute  the  bulk  of 
PGC-DTPAGd  molecular  weight  (up  to  80%  by 
weight  in  the  case  of  PL  with  40%  amino  groups 
modified  with  5kD  MPEG)  [18].  MPEG  protective 
chains in diluted water solutions were not expected to 
form coordination bonds with free paramagnetic ions. 
Therefore,  the  percentage  of  Gd  by  weight  in 
PGC-DTPAGd is always lower than in PLL-GdDTPA 
prepared  from  PLL  with  the  same  degree  of 
polymerization and ranges between 5-6% of dry co-
polymer  weight.  The  calculated  longitudinal  molar 
proton relaxivity of Gd was similar in the presence or 
in the absence of MPEG chains (i.e. the efficiency of 
Gd  to  increase  longitudinal  (spin-lattice)  relaxation 
rate of water protons, r1= R1/[Gd]= 12-14 [mmol.s.l]-1 
for poly(l-lysine)-GdDTPA and PGC-DTPAGd at 20 
MHz, 37○C) [18].  
The  estimation  of  mass  and  effective 
hydrodynamic radius of the obtained graft copolymer 
was necessary for understanding the in vivo behavior. 
Niether linear PEG standards nor protein standards 
were  suitable  for  estimating  the  mass  of 
PGC-DTPAGd.  For  example,  the  mass  determined 
from elemental analysis is approximately 2-times less 
than  the  mass  determined  by  size-exclusion 
chromatography (SEC) [20]. The difference between 
the  calculated  mass  of  PGC  from  protein  standard 
calibrated-SEC and true mass of PGC is due to the 
significant effect of highly hydrated large MPEGS side 
chains around PL on hydrodynamic diameter of PGC 
(see Fig. 2A). 
3.2. Immunogenicity and toxicity 
 Safety is a major concern in the case of all poly-
mers potentially useful for medical applications, and 
in  the  case  of  long-circulating  diagnostic  agents  in 
particular  [21].  A  number  of  large  macromolecules 
including  proteins  (serum  albumin),  synthetic  poly-
peptides,  polyamidoamines  (poly-l-lysine),  polyi-
mines and polysaccharides (dextran) can carry diag-
nostic labels and exhibit slow renal filtration (which is 
dependent on the size of the final molecule). Serum 
albumin (e.g. BSA) is a 66 kD protein and has 30-35 N-
 -lysine  amino  groups  that  can  be  potentially 
chemically  modified,  whereas  poly-l-lysine  of  the 
same mass has more than 500 -lysine residues, with 
the  majority  of  them  accessible  for  chemical 
modification.  And  although  a  variety  of  
macromolecules can be modified to carry diagnostic 
labels, many of them will have undesirable imaging 
characteristics  because  of  rapid  opsonization  (i.e. 
binding  of  complement  proteins  or 
immunocomplexes), removal by phagocytic cells (e.g. 
monocytes or Kupfer cell of the liver with the aid of 
scavenger or complement receptors), and breakdown 
and early excretion.  
Poly(ethylene  glycol)  is  not  toxic  for  animals 
even at high doses after systemic administration [22]. 
Remarkably, poly(ethylene glycol) and its derivatives 
substantially  decrease  immunogenicity  when 
chemically  attached  to  proteins  [23].  It  has  been 
hypothesised  that  the  modification  of  surface Theranostics 2012, 2(6) 
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-aminogroups by  highly hydrated polymer leads to 
the  masking  of  potential  antigenic  determinants  of 
proteins (reviewed in [24, 25]. We observed a similar 
effect with polymers containing poly(ethylene glycol) 
grafted to synthetic backbones. Presumably, grafted 
polymeric chains can potentially provide a "hydrated 
shell"  for  the  central  polymeric  carrier.  While 
protein-linked DTPAGd is immunogenic [18, 21], we 
did  not  observe  any  significant  immune  response 
against  DTPAGd  at  either  8  or  15  days  after 
PGC-DTPAGd intravenous (I.V.) injection in mice. To 
test  the  immune  response  to  PGC-DTPAGd 
components, MPEG and DTPAGd were conjugated to 
ovalbumin,  which  was  used  for  A  low-affinity 
response detected on day 8 had diminished by day 15 
(Fig. 2B). Whereas BSA-DTPAGd, used as a positive 
control and injected at a dose similar to Gd, elicited a 
substantial response to DTPAGd.  
Gadolinium-labeled  PGC-DTPA  did  not  show 
any  detectable  toxic  effects  in  two  rodent  species 
under  study.  We  detected  no  weight  loss  or  renal 
toxicity in mice injected at 30 times the projected MR 
imaging  dose  (0.6  mmol  Gd/kg,  a  total  of  50  mg 
PGC-DTPAGd/animal, one month observation) or in 
rats injected with a total dose of 0.2 mmol/kg (a total 
of 125 mg of PGC-DTPAGd/animal, 5-6 consecutive 
injections for 2 weeks) [18, 26].  
3.3. Biokinetics and biodistribution of PGC 
labeled with hydrophilic groups. 
 The grafting of long-chain MPEGs results in a 
significant increase in the blood half-life of a backbone 
polyamino  acid  (e.g.  PLL)  when  compared  to 
non-modified PL (Table 1). However, the presence of 
high  amounts  of  MPEG  in  the  aqueus  solution  of 
PGCs  may  increase  viscosity  and  hamper  i.v. 
administration  of  concentrated  formulations.  In  an 
attempt to decrease the size of protective chains while 
preserving  longievity  in  blood,  we  prepared  PGC 
with MPEG ranging in mass from 0.75 to 5 kD, and 
tested these compounds in vivo. Our results indicate 
that 2-5 kD MPEGs definitely prolong the circulation 
in vivo while 0.75 kD MPEG does not [20]. A notable 
decrease  in  renal  uptake  was  observed  with  the 
increase of MPEG chain length. A biphasic pattern of 
elimination was typical for 2-5 kD MPEG, however, 
0.75kD MPEG-modified PGC exhibited a very rapid 
blood clearance similar to that of PL-DTPAGd with a 
major  short  phase  (blood  half-life  t1/2=  0.6  h).  A 
monoexponential blood clearance was only seen for 
MPEG5-containing PGC. The use of MPEG succinyl 
succinate for grafting allows the introduction of addi-
tional biodegradable ester bonds into the protective 
chains  which  tend  to  break  down  after  prolonged 
incubation with plasma, while metal cation chelation 
to DTPA showed excellent stability even in the pres-
ence of an excess of apo-transferrin [17] (Fig. 3A,B). A 
typical time course of PGC-DTPAGd biodistribution 
in  rats  harboring  ectopic  mammary  R3230 
adenocracinomas  is  shown  in  Fig.  3C.  The 
biodistribution  confirms:  1)  long  circulation  time  in 
blood; 2) some residual uptake of PGC in the kidneys; 
3) the uptake of PGC in tumors due to the enhanced 
permeability and retention (EPR) effect.  
 
Table 1. Properties of PGC-DTPA(Gd) synthesized using poly-l-lysine hydrobromide with a degree of polymerization of 
252 and a MW(LALLS) of 41.8 kD. 
MPEGS 
mass  
 
Number MPEGS 
residues/ 
PGC molecule 
Calculated av-
erage mass of 
PGC-DTPAGd 
Apparent mass of 
PGC-DTPAGd, by 
SEC
a
 
Hydrodynamic diame-
ter, mean+SD, nmb 
 Gd, % by weight   Blood 
half-life, hc  Calculated  Elemental analysis 
0  0  136,000  315,000  NM  24.7   16.6±0.5  0.3d  
750  90  180,000  400,000  NM  ND    0.6 15e 
2000  96  300,000  602,000  4.0+2.0  12.0   13.4±0.3  1.1 8.2e 
5000  92  560,000  1160,000  10.3+2.0   6.0   7.0±0.2  14.1d  
a- determined using protein mass standards for SEC;  
b- determined using photon correlative spectroscopy  
c- determined in rats (n=3/ time point), mean values are presented; 
d- monoexponential fitting;  
e- biexponential fitting of experimental data; first value - short component, second value - long  
 component 
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Figure 2. Protective elements in PGC and low immunogenicity. A – an approximate 3D-model of a PGC fragment showing the 
major elements of the graft copolymer structure (courtesy of Terence O’Loughlin, M.D., MGH-CMIR); B – the comparison of immune 
response to DTPAGd conjugated either to a protein (BSA-DTPAGd, open symbols) or to PGC (closed symbols) as determined by ELISA 
of blood plasma (in mice, n=3) using ovalbumin conjugated to DTPAGd for detecting the formation of antibodies. The numbers in 
parenthesis indicate the time interval before Gd injection and ELISA test. Adapted from [18]. 
 
 
 
Figure 3. Resistance to transchelation, degradation in blood, and biodistribution in vivo. A- size exclusion HPLC profiles 
(scintillation  radioactivity  detector)  of  111In-labeled,  Gd-saturated  sample  of  PGC-DTPA  incubated  in  saline  or  PBS/2  mg/ml 
apo-transferrin for 48 h; B- size exclusion HPLC of 111In-labeled, Gd-saturated sample of PGC-DTPA incubated in PBS or whole blood for 
48 h. The arrow shows the shift of the peak migration and the formation of a shoulder indicating biodegradation.  C – residual 
blood-corrected biodistribution of PGC-DTPA (111In-labeled, Gd-saturated) in R3230 AC implanted Fisher rats (n=4 for each time point). 
Adapted from [17]. 
 
4. Applications in imaging 
4.1. Quantitative MR and radioisotope imaging 
of blood volume and dynamics  
 Most pathological processes involve changes, at 
some level, in vascular structure or function. In some 
cases (atherosclerosis, stroke, and heart disease), these 
changes cause the disease and in other cases (diabetes, 
cancer, and inflammation) these changes promote and 
exacerbate the spread/pathology of the disease. Thus 
high resolution morphological and functional vascu-
lar imaging is the center stone of radiological methods 
for the diagnosis and staging of multiple diseases, as 
well as in treatment planning and evaluation (such as 
determining the metastatic potential of tumors or the 
amount of salvageable brain area after stroke).  
 Gadolinium labeled PGC (PGC-DTPAGd) ena-
bles  high-quality,  high  resolution  images  of  blood 
vessel  morphology  [18],  in  rodents  and  rabbits  [27] 
that  can  be  obtained  at  various  magnetic  field Theranostics 2012, 2(6) 
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strengths  (1.5-9.4T),  Fig.  4.  After  injecting 
PGC-DTPAGd, we were able to track arteriovenous 
circulation  on  the  obtained  images  by  using  angio-
graphic  MR  pulse  sequences.  Both  the  arteries  and 
veins of small diameter (0.25-1 mm) became readily 
discernible for 3 h after the injection. We achieved a 
level  of  contrast  equivalent  to  that  achieved  by  the 
low  mass  contrast  agent  DTPAGd,  but  at  a  much 
lower  dose  of  Gd  (20  µmol  PGC-DTPAGd  versus 
100-200  µmol  DTPAGd).  With  the  introduction  of 
high  field  MRI  (9.4T)  much  higher  signal-to-noise 
images could be obtained by injecting approximately 
0.15  mmol  PGC-DTPAGd/kg  (Fig  4).  We  further 
demonstrated the feasibility of PGC-DTPAGd assist-
ed detection of slow gastrointestinal bleeding [28]. In 
the above model study we showed that at a dose of 35 
μmol/kg  PGC-DTPAGd  we  could  clearly  delineate 
small  volumes  of  blood  in  the  gastrointestinal  (GI) 
tract (stomach and small intestine), whereas the same 
volume  of  Gd-free  blood  was  not  detectable.  These 
results demonstrate that due to the long blood half life 
of PGC, blood pool imaging can potentially be helpful 
in detecting venous as well as arterial bleeding and in 
imaging intermittent GI bleeding over time.  
 The  advantages  of  DTPAGd-labeled  PGC  for 
determining blood flow and blood volume in animal 
models  of  disease  have  been  assessed  in  several 
studies [29, 30]. Unlike radiochemical CAs, the signal 
changes generated by MR blood pool agents do not 
directly  reflect  their  concentration  since  MR  signal 
changes do not arise due to CA itself but instead are 
the consequence of CA effects on relaxation properties 
of surrounding proton spins. Because water exchange 
occurs  between  blood  and  the  extravascular  space, 
protons of water molecules carry magnetization out of 
the blood and into the extravascular space, rendering 
inaccuracies  in  the  calculation  of  hemodynamic  pa-
rameters. In an effort to offset these inaccuracies, most 
studies of blood flow and volume make a priori as-
sumptions about the proton exchange rate (that it is 
either zero or rapid) for the organ or system under 
investigation. The use of a strictly intravascular CA 
such as PGC-DTPAGd allowed estimating the accu-
racy  and  precision  of  blood  volume  measurements 
[31].  When  assuming  fast  exchange  of  protons  be-
tween  blood  compartments,  the  true  blood  volume 
was  generally  overestimated  and  when  assuming 
slow or no exchange the opposite was true (an un-
derestimation  occurred).  As  for  the  use  of 
PGC-GdDTPA in measuring blood volume, we found 
that the best approach was to assume contributions 
from fast and slow proton exchange to be equal while 
carefully selecting imaging parameters. Such consid-
erations were found to be of upmost importance in the 
accurate  assessment  of  blood  volume  in  an  animal 
model of tumor neovascularization (see section 4.2). 
 
 
Figure  4.  Imaging  of  vascular  supply  using  PGC-DTPAGd.  A- maximum intensity pixel (MIP) projection image of blood 
circulation in a mouse obtained using gradient-echo pulse sequence (1.5T, GRASS, TR/TE 60/8, FA 60, 2NEX, 8 cm field of view) after 
injecting PGC-DTPAGd at 25 µmol Gd/kg; B- a MIP image showing circulation in the head of a rat (imaging parameters similar to that of 
A); C – an improvement in imaging detail of rat cerebral circulation at 9.4T results from increased dose of PGC-DTPAGd (150 µmol 
Gd/kg) due to the lower molar relaxivity of Gd3+ at high magnetic fields. Adapted from [18, 103]. 
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 Based on the above findings we assessed trans-
vascular  water  exchange  in  an  acute  stroke  model 
using  PGC-DTPAGd  [32].  Because  low  molecular 
weight  DTPAGd  permeates  the  compromised  brain 
vessels,  its  presence  in  the  extravascular  space  is 
widely  used  for  detecting  this  pathology  in  stroke. 
However early brain ischemia may not be detectible 
using  conventional  DTPAGd-enhanced  MR  angi-
ography [33] [34]. We measured the early movement 
of water molecules out of the vasculature in mice with 
middle  cerebral  artery  occlusion  by  acquiring  MR 
images after the injection of PGC-DTPAGd. We found 
that water exchange across the vessel walls increased 
early (within 1h) after the middle cerebral artery oc-
clusion  and  apparent  diffusion  coefficient  (ADC) 
values in the same brain regions decreased over time 
consistent with the progression of edema due to in-
creased intracellular volume.  
 Subsequently  we  tested  a  similar  PGC  com-
pound obtained by chelating the paramagnetic metal 
dysprosium with PGC-DTPA. We found that a blood 
volume-dependent tissue signal (generated by T2- or 
T2*-weighted  pulse  sequences)  can  be  monitored 
continuously,  without  interfering  with  arterial  spin 
labeling  technique,  thereby  allowing  simultaneous 
blood volume and cerebral blood flow measurements 
(CAPTIVE  imaging)  [35].  Due  to  a  very  low  r1  of 
dysprosium PGC-DTPADy does not interfere with the 
ASL induced signal, and thus affords an advantage 
over imaging with DTPAGd. CAPTIVE allowed high 
spatial resolution imaging of blood flow and volume 
changes occurring after middle cerebral artery occlu-
sion in rats and these hemodynamic changes could be 
correlated with ischemia induced tissue damage. In a 
separate study [36] the CAPTIVE method was used 
successfully to measure hemodynamic changes dur-
ing hemorrhagic hypotension.  
Collectively, our results with PGC as a carrier for 
MR imaging CAs  suggest that steady-state imaging 
with long-circulating agents potentially has important 
advantages for a number of MR clinical applications. 
These  should  be  of  greatest  utility  in  cases  such  as 
stroke and GI bleeding when timely diagnosis is key 
to positive patient outcome.  
 We have also developed PGC-DTPA for blood 
pool  imaging  in  nuclear  medicine  applications.  We 
hypothesized that the availability of a long-circulating 
synthetic molecule that could be easily labeled with 
gamma-emitting isotopes would obviate the need to 
use human blood components as carriers for isotopes 
and therefore would be a substantial improvement in 
patients' and operators' safety. Our major expectation 
was that PGC-DTPA could be formulated into a kit 
form  which  needs  only  the  addition  of  pertechne-
tate-99m  solution  to  obtain  a  [99mTc]-labeled  injec-
tion-ready  preparation  for  imaging  left  ventricular 
ejection fraction in oncology patients undergoing po-
tentially cardiotoxic treatments [37].  
 To  obtain  a  labeling  kit,  we  combined 
PGC-DTPA with a buffering solution in the presence 
of Sn(II) to enable reductive conversion of pertechne-
tate to a Tc oxocomplex [37]. After testing the kit in 
vitro and in three animal species [37] (representative 
SPECT/CT  image  in  rats  Fig.  5A)  we  tested 
PGC-DTPA[99mTc]  in  a  phase  I  clinical  trail  that 
showed promising results. Twenty mCi (70 MBq) of 
the compound were injected I.V. and serial anterior 
and posterior whole body images were collected im-
mediately and after a delay [38] (Fig. 5B). The com-
pound  showed  the  expected  distribution  and  the 
heart  and  major  blood  vessels  were  clearly  distin-
guishable up to 24 h post injection. The blood half life 
of  the  compound  was  20.6  ±  2.3  hr.  In  four  of  the 
volunteers 22.1% ± 2.5% of the compound had been 
excreted  through  the  kidneys  24  hr  after  iv  admin-
istration,  while  the  other  two  volunteers  showed  a 
greater  distribution  of  the  agent  to  the  liver  and 
spleen presumably due to DTPA labeling instability 
and not due to immunogenicity. A combination of the 
PGC  long  blood  half-life  with  the  advantages  of  a 
simple labeling protocol make this synthetic copoly-
mer kit a potential substitute for blood products in 
blood pool imaging under the conditions when other 
blood  pool  imaging  modalities  fail  to  produce  ade-
quate results.  
4.2. Imaging of tumor neovascularity. 
 Neovascularization is one of the key character-
istics of tumor growth [39]. Although neovascularity 
of  a  solid  tumor  does  not  necessarily  imply 
malignancy,  extensive  sprouting  of  capillaries  in 
malignant tumors has been shown to correlate with 
metastatic  potential  [39].  Non-invasive  detection  of 
altered tumor vessels is potentially important in bi-
opsy  planning,  staging  and  in  treatment  evaluation 
(since decreased vascularized margins can be indica-
tive  of  tumor  regression).  We  initially  used 
PGC-DTPAGd-assisted MR imaging for detecting the 
increase of the diameter of host vessels, e.g. epigastric 
vein, as an early sign of tumor progression in a rat 
model  of  mammary  adenocarcinoma  [40].  Six  to  8 
days  after  tumor  implantation,  vessels  at  the  tu-
mor/host interface became clearly visible by MRI. At 
later stages of tumor development, we observed for-
mation of tumor blood vessels with abnormal mor-
phology  (Fig.  6A-C).  Time-delayed  imaging  of  the 
same animals (48 h post IV administration) revealed 
the  enhanced  leakage  of  PGC  from  immature  and Theranostics 2012, 2(6) 
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permeable tumor blood vessels (Fig. 6D-F) Therefore, 
PGC-DTPAGd-generated vessel enhancement of MR 
signal is effective in tracking the developing vascular 
tumor  architecture  non-invasively  in  vivo.  The 
method is sensitive in the whole volume of the tumor 
at even early time points and has the capacity to be 
instrumental in detecting areas of enhanced vascular 
permeability.  
 We  further  tested  whether  PGC-DTPAGd  dis-
tribution reflects tumor and interstitial relative blood 
volume fractions in a model of rat glioma  [41]. We 
used consecutive I.V. injections of PGC-DTPAGd and 
DTPAGd where the first injection selectively saturates 
the blood signal so that the second I.V. injection of 
DTPAGd alters the MR signal of the tumor interstit-
ium due only to its escape through abnormally per-
meable vessels of the tumor. Therefore, a simple sub-
traction of MR images obtained using the two contrast 
agents  allowed  mapping  of  relative  vascular  (VVF) 
and relative interstitial volume fraction (IVF) of the 
tumor within the same imaging slice, assuming very 
slow water exchange between compartments (which 
is valid given the use of specific pulse sequences). We 
were able to map patterns of intratumoral and inter-
tumoral  heterogeneity  of  both  volume  fractions  at 
submillimeter  pixel  resolution  and  these  patterns 
agreed with tissue histology data. 
 
 
 
Figure 5. PGC as a blood pool imaging agent. A- a fusion SPECT/CT image of a rat 30 min after the injection of 99mTc-labeled PGC 
(2 mg PGC-DTPA/kg, 1 mCi 99mTc/rat). The image was obtained using NanoSPECT/CT (Bioscan Inc.); B- an image obtained in a healthy 
volunteer during Phase I clinical trials. Serial anterior whole-body images are shown taken immediately (30 min) and 2 h after the injection 
of 25 µg PGC-[99mTc]DTPA/kg (total dose - 20 mCi 99mTc). Note the distribution in the blood pool and low uptake in the lung, spleen and 
liver. Adapted from [38]. 
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Figure 6. MR imaging of tumor neovascularity and interstitial leakage in a rat model of adenocarcinoma. A-C- a MIP 
projection (A) and two non-consecutive MR imaging slices obtained 30 min after I.V injection of PGC-DTPA(Gd) in rats with R3230 
adenocarcinoma. D-F – MR images obtained in the same animal 48 h after the injection of PGC-DTPAGd. Note accumulation in the tumor 
at 48 h (the location of the tumor is shown by arrowheads). For MR imaging conditions see Figure 4A, legend. Adapted from [40]. 
 
 
 The  use  of  PGC-DTPAGd  was  further  refined 
for  measurement  of  absolute  blood  and  interstitial 
volumes in a murine model of prostate cancer  [42]. 
The measurements of blood and interstitial volumes 
calculated from Gd-based methods could be skewed 
when a prior assumptions of either large or negligible 
water exchange between the inter and extravascular 
compartment were made [31]. The is primarily due to 
the fact that some tumors (for example rat brain 9L 
gliosarcoma model) have significantly different water 
exchange rates than the surrounding normal tissue. In 
this  study,  we  modeled  a  range  of  water  exchange 
rates in order to establish a more precise method for 
quantification of absolute blood and interstitial vol-
ume  in  mice  bearing  slow  growing  MDA  PCa  2b 
prostate  tumors.  Results  showed  that  unlike  more 
aggressive  tumors, MDA  PCa 2b tumors  have very 
similar intra-/extravascular water exchange rates and 
blood  volumes  for  tumor  and  non-tumor  compart-
ments. This raises the intriguing possibility that a dual 
tracer method using a large molecular weight, strictly 
intravascular CA such as PGC-DTPAGd in combina-
tion with DTPAGd may allow differentiation of ag-
gressive versus slow-growing tumors. In a model of 
MCF-7  mammary  adenocarcinoma  overexpressing 
VEGF,  PGC-GdDTPA  revealed  significantly  higher 
vascular volume fractions in VEGF expressing tumors 
(8.9  ±  2.1)  compared  to  control  tumors  (1.7  ±  0.5, 
p<0.003). VEGF overexpressing tumors  had 1.6 fold 
higher microvascular density as assessed by histology 
[43]. Overall, the ability to separately measure relative 
vascular and extravascular tissue volume fractions in Theranostics 2012, 2(6) 
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the same study may provide new algorithms for as-
sessing tumor aggressiveness and response to treat-
ment. In addition, because the size and make up of the 
tumor  insterstitial  volume  will  affect  the  ultimate 
concentration and distribution of chemotherapeutics 
that  extravasate  from  the  blood  pool  and  reach  the 
tumor, the knowledge of the IVF will be important in 
treatment  planning  and  assessment  of  tumoral  re-
sponse to therapy.  
 In view of the latter, PGC-DTPAGd is especially 
useful  for  monitoring  anti-angiogenesis.  Since  our 
studies  in  a  tumor  model  overexpressing  VEGF 
demonstrated  a  pro-angiogenic  increase  of  tumor 
blood volume, we tested whether PGC-DTPAGd can 
also be used to detect anti-angiogenic effects of the 
experimental  VEGF  type  2  receptor  tyrosine  kinase 
inhibitor (VEGFR2-TKI) [44]. By using a steady-state 
blood pool imaging technique we were able to detect 
a  very  early  decrease  in  tumor  blood  volume  (Vb) 
after treating mice with two doses  of VEGFR2-TKI, 
which in turn resulted in a decrease of vascular den-
sity and tumor cell apoptosis (Fig. 7A,B). By measur-
ing the dependence of Vb measurement on flip angle 
using a gradient echo pulse sequence, we determined 
that in ectopic and orthotopic colon adenocarcinomas, 
a Vb change from 2.4% to 1.1% (at high flip angle of 
80o [45]) was detectable only in tumors as opposed to 
the  normal  muscle  blood  volumes,  which  were  not 
decreased  by  VEGFR2-TKI  treatment  (Fig.  7C). 
Alongside with Vb, water exchange across the blood 
vessel wall, reflected by the slope of Vb dependence 
on flip angle, was also decreased in treated tumors 
but not in the muscle (Fig. 7C).  
Stable  synthetic  peptides  derived  from  type  1 
repeats of thrombospondin (TSP1) are a second class 
of molecules that we have tested for antiproliferative 
effects in a rat  model  of  glioma  [46].  After treating 
animals  with  TSP-1  derived  peptides,  we  observed 
suppression  of  glioma  growth  that  coincided  with 
apparent  inhibition  of  de-novo  blood  vessel  for-
mation, i.e. according to our PGC-DTPAGd enhanced 
MR imaging, TSP-1 derived peptides did not induce 
anti-angiogenesis but instead resulted in angiostasis. 
More recent MR studies have used both fluorescence 
and PGC-DTPAGd assisted MRI to show a reduction 
in functional de-novo vessel formation occurring after 
adoptive transfer of GFP/Noggin-expressing human 
endothelial cells in immunocompromised mice  [47]. 
The  effect  of  Noggin  (a  potent  antagonist  of  bone 
morphogenetic protein signaling) on tumor prolifera-
tion and metastases awaits further study, but should 
be  readily  assessed  with  the  use  of  PGC-DTPAGd 
-based perfusion imaging methods. 
 
Figure 7. PGC-DTPAGd in imaging of anti-angiogenesis. A,B- histology of MV522 tumors prior to (A) and after treating animals 
with VEGFR2 tyrosine kinase inhibitor (TKI). Anti-CD31 staining (blue) reflects changes in vascular diameter and density. C – The 
dependence of absolute tissue blood volume fraction (Vb), measured after the injection of 50 µmol Gd/kg of PGC-DTPAGd from flip angle 
of MR SPGR pulse sequence that reflects changes of Vb due to TKI treatment. The slopes reflect changes in water exchange rates across 
the blood vessel wall. Adapted from [44]. Theranostics 2012, 2(6) 
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4.3. Imaging the tumor microenvironment  
 Some  of  the  properties  of  the  tumor  environ-
ment can potentially be imaged by using probes that 
respond  to  altered  expression  of  hydrolases  due  to 
tumor-mediated  recruitment  of  stromal  cells  in  re-
sponse to rapid extracellular matrix remodeling, lo-
cally  elevated  angiogenesis,  and  apoptosis.  Specifi-
cally, protease expression and resultant extracellular 
matrix remodeling are regulated by complex interac-
tions  between  extracellular  matrix  components  and 
cells  populating  the  tumor,  including  mesenchymal 
and hematopoetic stromal cells [48].  
This  has been initially demonstrated by conju-
gating a near-infrared fluorescent (NIRF) dye, Cy5.5 
to PGC instead of GdDTPA (Fig. 8A).  
 
Figure  8.  PGC-based  protease-sensing  optical  imaging  probe.  A  –  a  computer-generated  model  (Molecular  operating 
environment, MOE) of a Cy5.5 cynaine dye-conjugated PGC showing 12 MPEG protective chains linked to a PL backbone (degree of 
polymerization - n=50) with the rest of N--amino groups modified by cyanine dye. A molecule of trypsin (a model serine protease, m.w. 
22 kD) is shown for comparison. The modeling was performed assuming a tetramolecular water hydration layer which is not shown 
(Laboratory of Molecular Imaging Probes, University of Massachusetts Medical School); B – change of Cy5.5 absorbance spectra before 
and after the trypsinolysis of N--cyanine modified PGC; C – the increase of Cy5.5 fluorescence excitation and emission values after 
treating PGC-Cy5.5 with trypsin which translates into an increase of fluorescence intensity detectable with imaging after the trypsinolysis 
(inset, , -T – in the absence and +T in the presence of trypsin). Adapted from [49]. Theranostics 2012, 2(6) 
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NIRF dyes are advantageous for in vivo optical 
imaging due to higher transmittance of the tissues in 
the near-infrared range of the spectrum (700–850 nm) 
as opposed to visible light, and lower emission of in-
herent biomolecules, thus allowing imaging of deeper 
tissue.  In  its  native  state,  the  PGC-Cy5.5  protease 
sensing probe has Cy5.5 molecules attached to the PL 
in close physical proximity and in a quenched state 
thereby  preventing  the  dyes  from  emitting  fluores-
cence upon light activation. After injection into tumor 
bearing animals, the probe accumulates in tumors due 
to  high  vascular  permeability,  and  is  subsequently 
exposed to high levels of tumor associated proteases. 
The  poly-L-lysine  backbone  of  the  probe  is  readily 
cleaved  by  serine  proteases,  which  apparently  can 
gain access to the backbone poly-l-lysine due to rela-
tively small diameters of the protein molecule (Fig. 
8A),  thereby  freeing  the  Cy5.5  and  rendering  PGC 
fluorescent, due to degradation of the copolymer and 
physical  separation  of  the  quenched  fluorophores 
(Fig. 8B,C).  
In  initial  tests,  this  protease-sensing  approach 
resulted in tumor associated fluorescence which was 
12 times higher than surrounding tissue and that al-
lowed detection of tumor xenographts in vivo [49, 50]. 
A family of cysteine proteases (possibly cathepsins B, 
H, or L) were determined to be the activating enzyme 
in this study although other proteases have since been 
shown  to  be  detectable  using  specifically  designed 
PGC based probes in a number of experimental mod-
els of cancer including those expressing cathepsin D 
[51,  52],  matrix  metalloproteinase  [53-55],  urokinase 
plasminogen-activator [56, 57] and caspase-1 [58]. The 
strength of this approach is that PGC attachment af-
fords  the  accumulation  of  the  probe  in  the  tumor, 
while  the  cleaved  products  are  sequestered  in  cells 
and tissues, thus allowing the amplification of signal 
over  an  extended  time  span  (>24  hrs).  Subsequent 
studies showed that the probe was taken up in some 
tumor cells but was mainly present in stromal cells 
recruited to the site of tumor formation (fibroblasts, 
monocytes/ macrophages, and dendritic cells) [59].  
 High  molecular  weight  activatable  probes 
should have a number of advantages in detection of 
tumors accessible to clinical optical imaging applica-
tions (i.e., those within 7-10 mm of the skin surface 
such as breast, prostate, and colon cancers), especially 
given  the  demonstrated  sensitivity  of  these  probes 
(detecting  subnanomole  levels  of  tumor-associated 
enzymes). These probes may prove valuable in dif-
ferential diagnosis and staging of cancers. For exam-
ple, cathespsin B-PGC probes allowed visualization of 
differential  cathespin  B  expression  in  a 
well-differentiated human breast cancer (BT20) and a 
highly  invasive  metastatic  human  breast  cancer 
(DU4475) in mice. Both types of breast cancers acti-
vated the NIRF probe so that tumors became readily 
detectable.  However,  in  tumors  of  equal  size,  there 
was a 1.5-fold higher fluorescence signal in the highly 
invasive breast cancer which correlated with a higher 
cathepsin-B protein content [60] (Fig. 9). Furthermore, 
these  probes  should  have  utility  in  assessing  thera-
peutic response as indicated in a study that proved 
feasibility of PGC-based metalloproteinase-3 sensing 
probe for detecting the effect of oncolytic adenovirus 
in tumors [55].  
 
 
Figure. 9. Imaging of PGC-Cy5.5 breakedown in mammary adenocarcinoma tumors. A- the immunoblot demonstrating a 
higher level of cathepsin B expression in DU4475 than in BT20 tumors, with the band integration profiles shown below the image of a blot. 
Reproduced  with  a  permission  from  [60];  B  –  ex vivo planar  imaging  of  Cy5.5  fluorescence  in  adenocarcinoma  samples  and  the 
corresponding in vivo image of orthotopic tumors implanted in the same animal bilaterally (shown by yellow arrowheads). The animals 
were injected with 2 nmol of Cy5.5 conjugated to PGC 24 h prior to optical imaging. Theranostics 2012, 2(6) 
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4.4. Imaging markers of inflammation, 
atherosclerosis and diabetes 
 Diseases  with  different  etiologies  often  share 
common pathological phenotypes due to activation of 
the body‟s innate defense system which is triggered 
by nearly all external and internal insults. For exam-
ple,  vascular  changes  such  as  increased  vascular 
permeability accompany many diseases as the body 
attempts to increase blood flow to sites that will re-
quire efficient crossing of endothelial barriers by the 
cells of the immune system. Thus the PGC-based im-
aging agents described thus far may have utility in 
detecting  a  wide  range  of  diseases  because  of  their 
extravasation that is highly atypical in normal tissues. 
When used to detect E. coli induced infections in rats, 
Gupta  et  al  [61]  found  that  PGC-DTPAGd  yielded 
higher relative signal than [111In] labeled IgG due to 
the  lower  accumulation  of  PGC  in  normal  muscle 
tissue, and PGC-DTPAGd yielded similar signal rati-
os when compared to [111In]-labeled white blood cells 
and  [99mTc]-labeled  chemotactic  peptides.  Increased 
vascular permeability in infected tissue was regarded 
as the main reason for increased probe concentration 
in these areas. Similar permeability changes were de-
tectable with high-field MRI in the pancreatic vascu-
lature of type 1 diabetic rats [62], suggesting that MR 
imaging may be useful in detecting very early chang-
es in pancreatic vasculature that are believed to pre-
cede the onset of full disease.  
 PGC-based NIRF probes designed to target in-
flammation specific molecules have also been evalu-
ated in animal models of osteo- and rheumatoid ar-
thritis. The disease is characterized by early inflam-
matory  responses  in  which  the  release  of  ma-
trix-degrading enzymes (e.g., matrix metalloprotein-
ases (MMPs), cysteine proteases and cathepsin B), into 
the  synovial  fluid  cause  the  destruction  of  arthritic 
joints  due  to  the  degeneration  of  proteoglycan  and 
type II collagen. These events occur before morpho-
logical changes in joint structure can be detected. In 
two separate studies, cathepsin B activated NIR probe 
(PGC-Cy5.5) injected 24 hr prior to imaging resulted 
in a 3-fold increased fluorescence signal intensity in 
the affected joints of animals with experimentally in-
duced  arthritis  as  compared  to  control  animals  [63, 
64].  In  arthritic  animals  treated  with  the  an-
ti-inflammatory  drug  methotrexate  (35  mg  of 
MTX/kg 48 hours prior to probe injection), a signifi-
cantly  lower  fluorescent  signal  was  observed  as 
compared with untreated arthritic animals [63]. Alt-
hough X-ray and MRI have established utility in as-
sessing  the  progression  of  arthritis,  these  imaging 
methods detect changes only in more advanced dis-
ease. Thus NIR imaging of protease activated probes 
may  offer  an  advantage  in  detecting  the  earliest 
changes  in  the  disease,  when  anti-inflammatory 
therapy  has  the  greatest  chance  of  limiting  joint 
damage. In a more recent study, an altered form of the 
probe  was  used  in  which  poly-D-lysine  replaced 
poly-L-lysine  and  a  cathepsin  K  sensitive  peptide 
linker (GHPG-GPQGKC) was used for attachment of 
Cy5.5. This configuration resulted in a probe that was 
activatable only by cathepsin K [65], and was subse-
quently shown to detect osteoclast-derived cathepsin 
K  mediated  bone  degradation,  which  is  largely  re-
sponsible for bone resorption. 
 Atherosclerosis is another highly prevalent dis-
ease  that  is  now  considered  to  be  largely  linked  to 
vascular wall inflammation, and that may be detecta-
ble in its early stages with long circulating protease 
sensitive  PGC  based  probes.  An  early  pathological 
sign of the disease, the fatty streak, is an inflammatory 
lesion which is caused by the accumulation of mono-
cyte-derived  macrophages  and  T  lymphocytes  [66]. 
The  final  (and  often  fatal)  sequelea  of  the  disease, 
plaque rupture, is also associated with inflammation 
and has been correlated with the presence of highly 
activated macrophages [67, 68] which release proteo-
lytic enzymes that hasten plaque erosion and rupture. 
Experimentally  induced  atherosclerotic  lesions  in 
mice  were  successfully  imaged  using  fluores-
cence-mediated tomography (FMT) after the injection 
of  PGC-based  “activatable”  near-infrared  fluores-
cence (NIRF) probes for cathepsin B [69] and matrix 
metalloproteinases  (MMP2  and  MMP9)  [70].  Histo-
logical analysis showed co-localization of the probes 
with the targeted enzymes and with activated mac-
rophages. In addition, the probe mediated signal in-
crease could be diminished after treatment with pro-
tease inhibitors [70]. MMP sensitive probes have also 
been used to detect inflammatory responses occurring 
after myocardial infarction in mice [71].  
5. Applications in drug delivery 
5.1. Synthesis and applications of 
PGC-covalently linked drugs 
 Developments in synthetic chemistry and nan-
otechnology as well as improvements in the ability to 
re-engineer intrinsic biomolecules, have supplied the 
field with a number of promising drug delivery sys-
tems.  Ideally,  these  systems  should  be  capable  of 
protecting  the  active  therapeutic  as  it  travels  to  its 
organ of destination and then releasing the payload in 
full so that the drug concentration at the site of action 
is equivalent to the administered dose. When admin-
istered directly into the circulation, the drug-carrier 
complex should ideally exhibit low binding to serum 
proteins and be resistant to immediate uptake by the Theranostics 2012, 2(6) 
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reticuloendothelial system of the liver and spleen, or 
to rapid elimination  by the kidneys. Passage  of the 
drug through the tight junctions of the vascular en-
dothelial barrier and into the interstitium is another 
necessary step for delivery of a therapeutic molecule 
to its cellular destination. Ultimately, these character-
istics are conferred by the biochemical properties of 
the drug (such as its molecular weight and charge), 
and can also be influenced by the disease process it-
self. For example, many high molecular weight drug 
conjugates are known to accumulate in tumors to a 
greater extent than their free drug counterparts. This 
phenomenon  termed  “enhanced  permeability  and 
retention (EPR)” [72, 73] occurs because abnormal (i.e. 
„leaky‟) vascular structure in tumors are highly per-
meable to high molecular weight drug conjugates.  
 Methods  for  encapsulating  therapeutic  com-
pounds (such as the use  of liposomes or polymeric 
micelles) and for targeting these compounds to spe-
cific tissues and cells (such as attachment of antibod-
ies) have greatly widened the rage of compounds that 
can now be considered for development as therapeu-
tics [74].  
 The development of protected graft copolymers 
has made available a new and potentially very flexible 
method  for  drug  delivery.  The  potential  for  use  of 
PGC  based  compounds  as  drug  delivery  agents  is 
related not only to their ability to carry therapeutic 
molecules in a non-specific manner (“passive target-
ing”) through the vascular system and into the inter-
stitium, but to their ability to be modified so as to se-
lectively  target  molecules  in  the  extracellular  space 
(such as adhesion molecules or enzymes) or on the 
cell surface (i.e. “active targeting”). We  have found 
that  PGCs  have  a  slow  rate  of  biodegradation,  are 
biocompatible  (show  low  immunogenicity)  and  are 
eventually  eliminated  from  the  body  after  cleavage 
into small fragments. Additional advantages of PGCs 
include: 1) they accumulate at sites of high vascular 
permeability, 2) they are large enough to escape glo-
merular  clearance  (>  4nm  in  diameter)  even  when 
bound to drug, 3) they have a very slow RES clearance 
rate,  and  4)  they  can  potentially  decrease  immuno-
genicity of the drug to which they are bound.  
   Somewhat  surprisingly,  the  capacity  of 
PGC to „passively‟ accumulate in tumors was found to 
be  as  high  as  that  of  an  antibody  targeted  drug 
conjugate  [75].  Using  radionuclide  and  fluorescent 
labeled derivatives of PGC and BR96 (a tumor-specific 
chimeric  monoclonal  antibody  [76])  we  found  that 
PGC  slowly  accumulated  in  LX-1  human  small  cell 
lung  carcinoma  xenografts  (Fig  10A)  within  a  48  h 
period (to 5.2 ±1.7% of the injected dose per gram of 
tissue), while the antibody accumulation peaked at 24 
h  and  was  only  slightly  higher  at  6.0±  3.2%  ID/g 
(Fig.10B). Tumoral tissue distribution studies showed 
that roughly 43.9% of the PGC was associated with 
the tumor cell fraction while the remainder had ac-
cumulated in the interstitium. The large accumulation 
of PGC in tumor cells is likely due to its extravasation 
from leaky tumor vascular and subsequent retention 
in the tissue which serves as a depot for prolonged 
fluid phase endocytotic uptake by the cells. This hy-
pothesis is supported by in vitro studies showing that 
the copolymer showed negligible binding to the cell 
surface as compared to the antibody which showed 
high affinity binding (Kd of 4.5 x 10-7 M) followed by 
active vesicular internalization. In a subsequent study 
by  Choi  and  colleagues  [77],  this  approach  for 
achieving high concentrations of PGC bound drugs in 
tumors was shown to have therapeutic applicability 
when used to accumulate chlorine e6 (Ce6) in tumors. 
Ce6 is a porphyrin-based molecule that can be excited 
by  light  to  emit  fluorescence  and  simultaneously 
produce cytotoxic singlet oxygen, which causes local 
tissue  damage.  When  used  to  treat  xenografted 
HT1080 fibrosarcoma tumors in mice, a single dose of 
PGC-Ce6 followed by phototherapy was sufficient to 
decrease the tumor proliferation rate by one half.  
 In order to render PGC molecules more appli-
cable for the diagnosis and treatment of diseases that 
are not characterized by leaky vasculature, PGC can 
be targeted to specific tissues and cells by conjugation 
to  antibodies  and  other  targeting  moieties.  PGC 
probes were successfully targeted to cultured human 
endothelial cells by conjugating the F(ab‟)2 fragment 
of  monoclonal  anti-human  E-  selectin  monoclonal 
antibody (H18/7 [78]) to PGC modified by the addi-
tion  of  either  a  sulfhydryl-reactive  terminal  vinyl-
sulfonate  group  or  a  terminal  carboxyl  group  [79] 
(Fig. 11A). The two conjugation strategies resulted in 
compounds  with  similar  antibody/PGC  ratios  and 
apparent hydrodynamic radii. When added to human 
cultures,  125I  labeled  F(ab‟)2-PCG  showed  a  binding 
affinity  to  HUVEC  cells  expressing  high  levels  of 
E-selectin  (after  interleukin  1β  mediated  activation) 
that was 25 to 30 fold larger than the non-specific up-
take observed for non-stimulated HUVEC cells (Fig. 
11B,C). Furthermore the binding yield of the conju-
gate (expressed as a per cent of the total added anti-
body fragment) was almost 25% higher than for free 
F(ab‟)2  indicating  that  conjugates  with  the  higher 
F(ab‟)2 content were preferentially bound to the cell 
surface due to the increased avidity effect. This tar-
geted PGC probe should have indications for in vivo 
imaging of a host of diseases in which E-selectin ex-
pression  is  upregulated  in  association  with  inflam-
mation and angiogenesis.  Theranostics 2012, 2(6) 
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Figure 10. Targeted antibody and non-targeted PGC accumulation in the same LX-1 non-small cell lung carcinoma 
model. A – a time course of 111In-labeled monoclonal internalizing antibody BR96 and PGC uptake in LX-1 cells; B – biodistribution of 
111In-PGC (blue bars) and  111In-BR96 (grey bars) in LX-1 xenografts after intravenous injection in LX-1 bearing mice at 24h (n=4 
animals/time point). Adapted from [75]. 
 
Figure  11.  Human 
endothelial  cell 
activation-dependent 
uptake of anti-E-selectin 
conjugated  PGC.  A  – 
synthesis  of  anti-E  selectin 
targeted  PGC  using 
SATA-modified  F(ab’)2 
antibody  fragment 
conjugated  to 
heterobifunctional 
PEG-linkers  carrying  vinyl 
sulfone  groups;  B  – 
comparative  uptake  of 
non-conjugated  F(ab’)2 
antibody  fragments  and 
PGC- F(ab’)2 conjugate; C – 
fluorescence  microscopy  of 
IL-1  activated  and 
non-activated  cells 
demonstrating the uptake of 
both Cy5.5-labeled antibody 
fragment and PGC- F(ab’)2 in 
LX-1  cells.  Adapted  from 
[79]. 
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5.2. PGC- cisplatin complex and anti- 
proliferative activity  
 Our initial attempt at modifying PGCs for use in 
drug delivery entailed the synthesis of an adduct of 
the  antineoplastic  drug  cis-diamminedichloro-
platinum(II) (cDDP) and PGC [80]. cDDP and other 
antineoplastic drugs containing platinum are effective 
cancer  treatments  due  to  their  ability  to  cross-link 
DNA  and  thus  inhibit  division/  proliferation  of 
malignant  cells  [81].  The  motivation  in  creating  a 
modified  form  of  cDDP  was  to  increase  the 
bioavalibility  of  the  drug  after  I.V.  administration 
which  is  otherwise  very  low  due  to  cDDP‟s  rapid 
clearance by the kidney and irrevesible high affinity 
binding  to  plasma  protiens  [82,  83].  We  also 
hypothesized that binding to PGC would decrease the 
non-specific toxicity of the drug. Since Pt(II) is known 
to  form  complexes  with  carboxyl  residues  of  poly-
carboxylic acids, we hypothesized that succinyl resi-
dues attached to the backbone PGC with succinylated 
amino groups will similarly bind the aquated plati-
num(II)-diammine  complex.  We  found  that  simple 
co-incubation  of  cDDP  (12  mg/ml  in  DMF)  with  a 
water  solution  of  succinylated  PGC  (20  mg/ml  in 
water) at 37 °C resulted in an adduct of PGC-cDDP 
containing 4.3% of platinum by weight [80].  
 In vitro studies showed a 50% inhibition of hu-
man  BT-20  adenocarcinoma  cell  proliferation  at  a 
PGC-cDDP dose of 0.9 ± 0.2 μM as compared to 0.3 ± 
0.1  μM  for  free  cDDP.  Because  only  free  platinum 
complexes are effective in inhibitiing cell division, this 
result  suggest  that  cDDP  could  dissociate  from  the 
PGC complex in vitro. Indium-111 labeled PGC-cDDP 
was used to study the kinetics and biodistribution of 
the compound in vivo. We determined that due to a 
long blood half-life of 14 h, PGC-cDDP accumulated 
in  rat  mammary  tumors  (13762NF  and  R3230)  at  a 
dose that was 5-fold higher (2.5 to 3.5% of the injected 
dose/ gram of tissue) than a control adduct of cDDP 
with  a  short  half  life.  In vivo  imaging  using  radio-
labeled PGC-cDDP showed high regional activity in 
tumors,  whereas  the  control  adduct  accumulated 
mainly  in  the  kidneys.  This  pattern  of  distribution 
suggested  that  accumulation  in  tissue  results  from 
extravasation of cDDP and release of the drug in the 
tumor.  We  also  found  that  80%  of  the  PGC-cDDP 
adduct was eliminated from the circulation 48 h after 
I.V.  administration,  and  exhibited  a  nearly  5-times 
lower concentration in kidney.  
 In a following study [17] we assessed the thera-
peutic efficacy of PGC-cDDP in a cDDP-sensitive F9 
murine teratoma model. We injected identical doses 
(7.5 mg) of free or PGC-linked cDDP/kg every 3 d. 
Non-treated mice showed a 17-fold increase in tumor 
volume over 30 d after implantation. While animals 
treated with free cDDP showed reduction in tumor 
volume, they also showed an average 24% weight loss 
over the course of 6 d (2 treatments) with 100% mor-
tality. All animals treated with PGC-cDDP survived 
six consecutive treatments over 15 d and showed on 
average a 10% reduction in tumor volume, with 25% 
of the animals showing a complete regression of the 
tumors.  The  collective  results  from  these  studies 
demonstrate that that  PGC-succinate can serve as a 
high-capacity carrier for sustained release of cDDP in 
vivo. The drug conjugate shows less systemic toxicity 
than  the  free  drug  while  retaining  antiproliferative 
effectiveness.  
5.3. Non-covalent complexes of drugs and 
PGC 
The obvious advantages of the non-covalent as-
sociation  of  drugs  with  drug  delivery  carriers  is  in 
scalability,  in  the  ease  of  formulating 
drugs-containing compositions and in the lack of the 
need to chemically modify the drug molecules. The 
latter is a critical advantage in developing drug de-
livery formulations containing physiologically active 
peptides and proteins, many of which are capable of 
inactivation  during  chemical  modification.  The  de-
velopment of new formulations and devices for ad-
ministration of such peptides, proteins, as well as low 
molecular  weight  drugs  is  driven  by  the  need  to 
achieve  targeted  and  highly  specific  physiological 
effects. With respect to peptides and proteins, many of 
them  are  unstable  in  the  gastro-intestinal  tract  and 
therefore may need to be stabilized and protected or 
otherwise delivered via systemic circulation. In addi-
tion, peptides and proteins that have low molecular 
masses tend to have short biological half-lives due to 
their efficient removal from systemic circulation via 
kidneys. A fraction of these peptides and proteins can 
also be removed via reticuloendothelial uptake due to 
recognition by monocyte/macrophages and sinusoi-
dal endothelial cells exacerbated by opsonization of 
drug carriers by the complement system. As a rule, 
many peptides and proteins lose their activity in vivo 
due  to  proteolysis  (peptide  bond  cleavage).  Several 
drug delivery strategies can be useful to circumvent 
these  undesirable  effects  and  thus  increase  peptide 
and protein delivery in vivo. First, a pump can be em-
ployed  for  continuous  systemic  drug  infusion.  This 
strategy is proven efficient in clinical practice but may 
be  impractical  or  disadvantageous  for  outpatients 
because it restricts mobility, lowers quality of life and 
potentially results in I.V. line infections. Second, pep-
tides and proteins can be included in an implantable 
pump  with  a  membrane  allowing  diffusion  of  the Theranostics 2012, 2(6) 
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drug at a desirable release rate. Due to limited volume 
of these capsules, peptides and proteins are often used 
in a concentrated formulation, which leads to aggre-
gation resulting in loss of solubility and potential loss 
of specific activity. In most cases, the drug is released 
into  the  extracellular  space  and  is  carried  by  lym-
phatics.  Overall  concentration  of  peptide  or  protein 
may be affected by local lymph node activity and the 
efficacy of lymph node drainage at the implantation 
site. There is also a likelihood of host reaction to cap-
sule material. Third, the drug release system can be 
made biodegradable as a  result of encapsulation or 
inclusion  into  degradable  drug  delivery  vehicles  or 
carriers,  e.g.  polymeric  matrices,  particles  or  mem-
brane vesicles (liposomes). These delivery systems are 
usually either implantable or injectable. Implantable 
drug delivery systems are often placed under the ep-
idermis where the components of the system are usu-
ally slowly degraded as a result of biological activity 
of surrounding cells (i.e. as a result of the release of 
enzymes  degrading  chemical  bonds  that  hold  these 
implants together).  
The potential problems associated with the use 
of  delivery  compositions  containing  non-covalently 
bound  drugs  is  in  their  potentially  low  thermody-
namic  stability  in  solutions  that  necessitates  formu-
lating drug delivery compositions shortly before use. 
This disadvantage is not shared by PGC-based carri-
ers  that  can  be  subjected  to  lyophilization  together 
with the drug load due to their cryoprotective prop-
erties [84].  
5.3.1. PGC with hydrophobic cores (HC-PGC) as drug 
carriers  
Most peptides are purified after synthesis using 
reversed phase HPLC because of their affinity for al-
kyl groups covalently linked to the resin. Compared 
to resin with diameter of several microns, PGC has 
diameter of 10 to 50 nm. Despite these small diame-
ters, PGCs can be modified to contain a high density 
of long-chain fatty acid groups covalently linked to 
the PL backbone. Specifically, PGC can be synthesized 
to have a hydrophobic core consisting of stearic acid 
residues  covalently  linked  to  PGC  (Fig.  12A).  Such 
structure  has  certain  similarity  to  an  HPLC  carrier 
matrix that is covalently linked to octadecane groups. 
However, unlike a silanol-grafted HPLC matrix, the 
bonds in PGC are peptide and there are also MPEG 
protective  chains  covalently  linked  to  PL.  We  have 
previously  shown  that  such  “hydrophobic  core” 
(HC)-modified PGC is capable of reversibly binding 
peptides/proteins that are then capable of partition-
ing  into  hydrophobic  cores.  Alternatively,  they  can 
have  affinity  for  fatty  acids  and  thus  linked  to  the 
MPEG-grafted PL backbone. One such example, i.e. a 
computer-generated  model  of  leptin  non-covalently 
associated with aliphatic chains of HC-PGC, is shown 
in Fig. 12B. The peptide formulation with HC-PGC is 
accomplished by simple co-lyophilization of peptide 
with PGC followed by reconstitution in the injection 
buffer. Peptide formulations prepared in this manner 
demonstrate an extended blood circulation time after 
subcutaneous injection.  
In  general,  when  mixed  with  an  appropriate 
peptide that binds to HC, the resulting HC-PGC for-
mulation is expected to have an affinity-based peptide 
release mechanism. Under normal physiological con-
ditions  in  vivo,  one  would  expect  such  pep-
tide-HC-PGC complexes to dissociate due to a deple-
tion of free peptide pool (which depends on kinetic 
and thermodynamic stability of the peptide complex) 
which  can  accelerate  in  the  presence  of  fatty-acid 
binding proteins (e.g. serum albumin). However, due 
to steric hindrance imposed by the drug carrier-linked 
MPEG chains [85], which slows down the process of 
peptide displacement from the complex, such compe-
tition  is  likely  a  less  significant  factor  in  pep-
tide-HC-PGC  complex  dissociation  than  in  the  case 
where MPEG chains were absent. Hydrophilic MPEG 
chains  are  also  the  major  reason  why  HC-PGC  can 
exist as a colloidal solution in water. The overall hy-
drodynamic  diameter  of  HC-PGC  is  20  nm,  which 
circumvents the rapid kidney elimination but at the 
same  time,  enables  trafficking  from  subcutaneous 
sites to the blood, predominantly via the lymphatic 
system.  
Stabilization  by  PGC  is  particularly  useful  for 
peptides  that  rapidly  degrade  due  to  proteolysis. 
Most proteolytic enzymes in the blood have a Mich-
aelis constant (Km) in the range of several micromolar 
and most peptide receptor effective thermodynamic 
constants (Kd) are in the nanomolar range. Therefore, 
for  PGC  delivery  of  peptides  to  be  successful,  the 
complex of peptide-HC-PGC must have a Kd below 
the enzyme Km but above the receptor Kd (preferably 
<1uM).  In  the  past  we  tested  several  highly  potent 
small  peptides,  e.g.  glucagon-like  peptides  (GLP-1 
[19,  86-88],  GLP-2),  atrial  natriuretic  peptide  (ANP) 
and  leptin  as  potential  cargo  for  loading  HC-PGC. 
Below are some of the examples of our efforts directed 
at improving the stability  and bioavailability of the 
above peptides in vivo. 
5.3.2. Formulation and HC-PGC-mediated delivery of atrial 
natriuretic peptide (ANP) and leptin. 
 Atrial natriuretic peptide (ANP) and brain na-
triuretic peptide (BNP) are hormones produced by the 
heart  that  bind  to  natriuretic  peptide  receptor  A Theranostics 2012, 2(6) 
 
http://www.thno.org 
571 
(NPR-A) in target organs (blood vessels, kidney, ad-
renal,  and  heart)  and  generate  intracellular  cGMP 
[89]. They act through many parallel mechanisms to 
promote  cardiac  output  and  function,  i.e.,  they  an-
tagonize  the  renin-angiotensin-aldosterone  system 
[90-92], inhibit endothelin secretion, reduce systemic 
and  renal  sympathetic  activity,  increase  natriuretic, 
diuretic and vasorelaxant activity, and act directly on 
the kidney by dilating the afferent arteriole and con-
stricting the efferent arteriole [93, 94]. Thus natriuretic 
peptides  (NP)  can  be  viewed  as  inherent  biological 
molecules which are capable of producing most of the 
therapeutic  results  that  are  produced  by  first  line 
medications in use today for the treatment of heart 
failure  (HF).  In  addition,  NPs  may  offer  additional 
therapeutic benefits in treating patients with HF be-
cause  they  have  the  unique  ability  to  inhibit  TGF 
induced Smad translocation into the nucleus [95] and 
thus suppress myocardial fibrosis and hypertrophy or 
remodeling [96, 97] which would otherwise lead to 
further heart deterioration in patients with heart dis-
ease. Currently used treatments for HF directly inhibit 
cardiac  scarring  and  remodeling  and  thus  patients 
remain at a greater risk of future cardiac events and 
generally  poor  long-term  outcome.  Several  studies 
have shown benefits of ANP and BNP in preventing 
cardiac remodeling in ischemic injury. Patients who 
received an infusion of ANP or BNP during or for 2-3 
days  after  reperfusion  procedures  have  shown  de-
creased  infarct  size,  fewer  reperfusion  injuries,  and 
better  outcomes  (lower  incidence  of  readmission  to 
hospital) than controls [98]. 
 Advances in formulation chemistry over the last 
several  years  have  lead  to  increased  clinical  use  of 
NPs. ANP has a blood half-life of only 2.4 min and, as 
a result, has to be administered as an I.V. infusion. 
BNP also has a short half-life (12.1 min), and has been 
approved for the treatment of HF (also as an infusion). 
Unfortunately, bolus administration of large amounts 
of these peptides leads to hypotension and this effect 
persist  (10%  incidence)  even  if  lower  amounts  are 
injected  (0.025  µg/kg/min  of  carperitide)  [95]. 
Therefore, the development of a formulation of these 
peptides that has a longer blood half-life would po-
tentially  allow  patients  to  self-administer  the  drug 
outside  the  hospital  setting.  Our  goal  has  been  the 
development of a long-acting formulation of NP that 
can be used by patients who have received reperfu-
sion treatment to minimize future cardiac events and 
also to improve the long term outcome for those who 
have had mild myocardial infarction without receiv-
ing reperfusion treatment. We envision that the use of 
a PGC drug delivery system will allow the develop-
ment of injectable NPs (ANP and BNP) for use in pa-
tients with both mild and severe myocardial infarc-
tion, thus expanding the benefits of NP therapy to the 
majority  of  patients  suffering  from  coronary  heart 
disease.  
Leptin is a 16 kDa protein hormone that plays a 
key role in regulating energy intake and energy ex-
penditure, including appetite and metabolism. Leptin 
is  one  of  the  most  important  adipose-derived  hor-
mones. Leptin binds to the ventromedial nucleus of 
the hypothalamus, known as the "appetite center." A 
small group of humans possess homozygous muta-
tions for the leptin gene, which leads to a constant 
desire for food, resulting in severe obesity [99]. This 
condition can be successfully treated by the admin-
istration of recombinant human leptin [100, 101].  
 Our initial formulation of the HC-PGC complex 
with ANP and leptin was obtained by simply com-
bining  HC-PGC  and  the  corresponding  peptide  in 
isotonic buffered saline. This particular HC-PGC had 
a 20kD PL backbone and a high (55% of the N--amino 
groups)  modified  with  5kD  MPEG,  while  the  re-
maining  amino  groups  were  modified  by  acylation 
with stearic acid N-hydroxysuccinimide ester.  
After  1  h,  the  mixture  was  separated  using  a 
membrane of 100 kD cutoff that efficiently retained 
the  HC-PGC  complex.  The  free  and  the  HC-PGC 
bound ANP and leptin complexes were released from 
HC-PGC by treating them with 50% acetonitrile. The 
free and bound ANP and leptin were then analyzed 
by quantitative HPLC which enables estimation of the 
effective Kd value (Fig. 13A). We obtained a Kd value 
of 1.1 uM and determined that each 350kD HC-PGC 
carrier had on average 9 ANP molecules (mol. mass 
3kD) bound to it. Leptin formed a more stable com-
plex with HC-PGC (Fig. 13A). It should be noted, that 
estimation of effective Kd values reflecting the affinity 
of leptin and ANP to HC-PGC shows that the affinity 
correlates with GRAVY index (hydropathicity of lep-
tin  is  greater  than  ANP),  while  the  capacity  of 
HC-PGC  carrier  inversely  correlates  with  peptide 
mass (ANP<leptin).  
The  pharmacokinetic  profile  of  the  PGC-ANP 
formulation was determined in mice at various time 
points using ELISA of blood serum after intravenous 
administration of either free ANP or HC-PGC-ANP. 
Data  were  corrected  for  endogenous  background 
ANP.  It  should  be  noted  that  mice  have  a  higher 
metabolic rate than humans and the conversion factor 
(mouse to human) in dosing is 12:1 to 9:1 [102]. Hy-
drophobic  core-PGC  bound  ANP  had  an  extended 
circulation time compared to non-conjugated peptide 
and the extension of circulation was a function of the 
ratio of peptide to PGC (Fig. 13B). It is clear that re-
versible association of peptides with HC-PGC enables Theranostics 2012, 2(6) 
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sustained  release  after  systemic  administration  in 
mice  (2µg  peptide/animal,  n=4,  group)  with  a  re-
sultant large increase of area under the curve (AUC). 
 
 
 
Figure 12. HC-PGC as a drug carrier. A- a computer generated model of HC-PGC fragment with MPEG protective chains (shown 
space filled) and hydrophobic elements represented by fatty acid residues; B – a computer simulated representation of a leptin molecule 
binding to the hydrophobic “core”. Interacting surfaces are shown in green and grey for leptin and HC-PGC, respectively. The modeling 
is performed in MOE (Laboratory of Molecular Imaging Probes, Univesity of Massachusetts Medical School). 
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Figure 13. Polypeptide binding to HC-PGC and the release of HC-PGC bound cargo after the I.V. administration. A - 
The binding of atrial natriuretic peptide (ANP) and leptin to HC-PGC. The affinity to HC-PGC correlates with GRAVY index (hydro-
pathicity, leptin>ANP) and the capacity of HC-PGC carrier inversely correlates with peptide mass (ANP<leptin). B – reversible associ-
ation of ANP with HC-PGC enables sustained release after intravenous administration in mice (2µg peptide/animal, n=4, group) with a 
resultant strong increase of AUC compared to native ANP (Data provided by Pharmain Corp. Seattle WA). 
 
6. Conclusions and perspectives. 
As summarized in this review, the development 
of MPEG-protected polyamino acids has resulted in 
one of the most successful graft-copolymers to date 
for use as a carrier of potential diagnostic and thera-
peutic agents. Much of the potential of PGC lies in its 
versatility and ease of chemical modification and thus 
adaptation  for  delivering  both  convalently  and 
non-covalently linked cargo. PGC can be engineered 
as a covalent amphiphile that is capabe of binding to 
hydrophobic residues of small proteins and peptides 
resulting  in  a  “hydrophobic  core”  (HC)-modified 
PGC formulation that acts as an affinity-based peptide 
release mechanism. PGCs can also be made with zinc 
bridges  for  anchoring  zinc-binding  proteins. 
Alternately, non-covalent attachment can be designed 
for carriers containing physiologically active peptides 
and  proteins,  many  of  which  are  rendered  inactive 
upon  chemical  modification.  PGC-based  carries  can 
be synthesized relatively inexpensively and on a large 
scale  bases  for  commercial  applications.  Most  im-
portantly, these formulations are expected to remain 
stable in solutions or in lyophilized form for extended 
periods of time.  
 PGCs  offer  a  plurality  of  advantages  in 
comparison to other carries designed using PEGyla-
tion technology, e.g., multiple available linking sites 
for  drug  and  adaptor  molecules,  long  circulation 
times without compromised biodegradability, and no 
toxicity  or  immunogenicity.  The  safety  and 
biocampatability profile of PGC has in fact resulted in 
its  being  one  of  the  few  100%  synthetic 
non-proteinaceous macromolecules that has suceeded 
in passing the initial safety phase of clinical trials. This 
safety profile, along with the capability of MPEGs to 
protect the inner drug cargo from uptake and degra-
dation, forms the bases of its outstanding potential for 
use  in  the  development  of  a  wide  range  of  future 
therapeutic and diagnostic agents.  
 PGCs  conjugated  to  contrast  agents  such  as 
paramagnetic  gadolinium  are  capable  of  long 
circulation times after injection into the blood stream 
and  as  such  offer  advantages  in  angiographhic 
imaging  applications  used  for  the  assesment  of 
disease related vascular pathologies. These should be 
of  greatest  utility  in  cases  such  as  stroke  and  GI 
bleeding when timely diagnosis is key to positive pa-
tient outcome and will also be beneficial in chronic 
diseases such as cancer where assessment of tumor 
vascularity following therapeutic intervention is crit-
ical  for  further  treatment  planning.  In  addition,  be-
cause of their extravasation that is highly atypical in 
normal  tissues,  PGC-based  therapeutic  agents  can 
accumulate in diseased tissue in sufficient quantities 
to be of therapeutic benefit. On the same bases, ac-
cumulation  of  enzyme  sensing  PGC-based  imaging 
agents  allows  for  amplification  of  diagnostic  signal 
and thus higher sensitivity detection of pathological 
changes  occurring  at  the  cellular  and  tissue  level. Theranostics 2012, 2(6) 
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Furthermore,  PGC  technology  applied  to 
near-infrared fluorophores as optical imaging probes 
is also anticipated to have a number of advantages in 
detection of tumors accessible to clinical optical im-
aging applications (i.e., those within 7-10 mm of the 
skin surface such as breast, prostate, and colon can-
cers), especially given the demonstrated sensitivity of 
these  probes  (detecting  subnanomole  levels  of  tu-
mor-associated  enzymes).  These  probes  may  prove 
invaluable in the differential diagnosis and staging of 
cancers.  A  future,  but  as  yet  untested  use  of 
PGC-based carriers is in non-viral delivery of genes 
and  other  nucleotides  such  as  for  the  delivery  of 
siRNA.  As  a  non-modified  copolymer,  PGC  carries 
multiple  positive  charges  and  can  potentially  form 
polyionic  complexes  with  polyanions,  e.g.  plasmid 
DNA. 
 In  conclusion,  the  chemical  versatility,  safety, 
cost-effectiveness and tissue permeability and acces-
sibility  profile  of  PGC-based  compounds  offers  an 
exciting  pathway  for  future  development  of  highly 
sensitive and targeted diagnostics and therapeutics.  
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